Small ubiquitin-like modifiers inhibitors lower blood pressure via ERK5/KLF2-dependent upregulation of the eNOS/NO pathway

Abstract

Background Small ubiquitin-like modifiers (SUMO)ylation is a dynamic and reversible post-translational modification playing pivotal roles in the regulation of cancer, diabetes, heart failure, and neurological diseases. However, whether SUMO inhibitors also have anti-hypertension effect remains yet to be explored. Methods Blood pressure was monitored in spontaneously hypertensive rats (SHR) after Tannic acid (TA) administration for 4 weeks. The contents of nitric oxide (NO) and endothelin-1 (ET-1) in the serum of SHR were measured. Isolated endothelium-intact mesenteric artery rings were used to study relaxation effect of SUMO inhibitors. ERK5 SUMOylation was determined using coimmunoprecipitation (co-IP) and immunofluorescence (IF). NO levels were analyzed by IF. The expression levels of KLF2 and p-eNOS were semiquantified by Western blot analysis. The transcriptional activity of eNOS promotor was assayed using ChIP-PCR. Results Three SUMO inhibitors all reduced the phenylephrine (PE)-induced contraction of mesenteric artery rings in a concentration-dependent manner. Co-IP revealed that ponatinib promoted ERK5 SUMOylation, which was nulled following pretreatment with the SUMO inhibitors. IF displayed that TA increased ERK5 accumulation and its co-localization with SUMO-1 in the nucleus. ChIP-PCR unveiled TA-induced enhancement of KLF2-dependent eNOS promoter activity and upregulation of eNOS/NO expression in HUVECs. In vivo, TA significantly lowered the blood pressure and improved the vascular reactivity by activating the KLF2/eNOS/NO pathway. Additionally, the level of NO was elevated along with decreased ET-1 levels in the serum of SHR. Conclusion SUMO inhibitors inhibit ERK5 SUMOylation to promote KLF2-eNOS/NO signaling, indicating their therapeutic potential for the treatment of hypertension.

Keywords

hypertension / SUMO inhibitor / ERK5 / SUMOylation / KLF2

References

[1] Mills K T, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol, 2020; 16(4): 223-237. doi: 10.1038/s41581-019-0244-2

[2] Poulter N R, Prabhakaran D, Caulfield M. Hypertension. Lancet, 2015; 386(9995): 801-812. doi: 10.1016/S0140-6736(14)61468-9

[3] Dehnavi S, Sadeghi M, Penson P E, et al. The role of protein SUMOylation in the pathogenesis of atherosclerosis. J Clin Med, 2019; 8(11): 1856. doi: 10.3390/jcm8111856

[4] Kukkula A, Ojala V K, Mendez L M, et al. Therapeutic potential of targeting the SUMO pathway in cancer. Cancers (Basel), 2021; 13(17): 4402. doi: 10.3390/cancers13174402

[5] Paudel R, Fusi L, Schmidt M. The MEK5/ERK5 pathway in health and disease. Int J Mol Sci, 2021; 22(14): 7594. doi: 10.3390/ijms22147594

[6] Roberts O L, Holmes K, Muller J, et al. ERK5 and the regulation of endothelial cell function. Biochem Soc Trans, 2009; 37(Pt 6): 1254-1259.

[7] Woo C H, Shishido T, Mcclain C, et al. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res, 2008; 102(5): 538-545. doi: 10.1161/CIRCRESAHA.107.156877

[8] Shishido T, Woo C H, Ding B, et al. Effects of MEK5/ERK 5 association on small ubiquitin-related modification of ERK5: implications for diabetic ventricular dysfunction after myocardial infarction. Circ Res, 2008; 102(11): 1416-1425. doi: 10.1161/CIRCRESAHA.107.168138

[9] Erazo T, Espinosa-gil S, Dieguez-martinez N, et al. SUMOylation is required for ERK 5 nuclear translocation and ERK5-mediated cancer cell proliferation. Int J Mol Sci, 2020; 21(6): 2203. doi: 10.3390/ijms21062203

[10] Paez-mayorga J, Chen A L, Kotla S, et al. Ponatinib activates an inflammatory response in endothelial cells via ERK5 SUMOylation. Front Cardiovasc Med, 2018; 5: 125. doi: 10.3389/fcvm.2018.00125

[11] Yang T, Shu F, Yang H, et al. YY1: A novel therapeutic target for diabetic nephropathy orchestrated renal fibrosis. Metabolism, 2019; 96: 33-45. doi: 10.1016/j.metabol.2019.04.013

[12] Wu W, Geng P, Zhu J, et al. KLF2 regulates eNOS uncoupling via Nrf2/HO-1 in endothelial cells under hypoxia and reoxygenation. Chem Biol Interact, 2019; 305: 105-111. doi: 10.1016/j.cbi.2019.03.010

[13] Huai R, Han X, Wang B, et al. Vasorelaxing and antihypertensive effects of 7, 8-dihydroxyflavone. Am J Hypertens, 2014; 27(5): 750-760. doi: 10.1093/ajh/hpt220

[14] Vertegaal A C O. Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol, 2022; 23(11): 715-731. doi: 10.1038/s41580-022-00500-y

[15] Brown M D, Sacks D B. Protein scaffolds in MAP kinase signalling. Cell Signal, 2009; 21(4): 462-469. doi: 10.1016/j.cellsig.2008.11.013

[16] Ohashi Y, Kawashima S, Hirata K, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest, 1998; 102(12): 2061-2071. doi: 10.1172/JCI4394

[17] Komaravolu R K, Adam C, Moonen J R, et al. Erk 5 inhibits endothelial migration via KLF2-dependent down-regulation of PAK1. Cardiovasc Res, 2015; 105(1): 86-95. doi: 10.1093/cvr/cvu236

[18] Fulton D J. Transcriptional and posttranslational regulation of eNOS in the endothelium. Adv Pharmacol, 2016; 77: 29-64.

[19] Pazoki R, Dehghan A, Evangelou E, et al. Genetic predisposition to high blood pressure and lifestyle factors: associations with midlife blood pressure levels and cardiovascular events. Circulation, 2018; 137(7): 653-661. doi: 10.1161/CIRCULATIONAHA.117.030898

[20] Weinberger M H. The cold pressor test: a new predictor of future hypertension? Arch Intern Med, 2008; 168(16): 1732. doi: 10.1001/archinte.168.16.1732

[21] Zhao Q, Gu D, Lu F, et al. Blood pressure reactivity to the cold pressor test predicts hypertension among Chinese adults: the gensalt study. Am J Hypertens, 2015; 28(11): 1347-1354. doi: 10.1093/ajh/hpv035

[22] Radin J M, Neems D, GogliA R, et al. Inverse correlation between daily outdoor temperature and blood pressure in six US cities. Blood Press Monit, 2018; 23(3): 148-152. doi: 10.1097/MBP.0000000000000322

[23] Kim J Y, Jung K Y, Hong Y S, et al. The relationship between cold exposure and hypertension. J Occup Health, 2003; 45(5): 300-306. doi: 10.1539/joh.45.300

[24] Lewington S, Li L, Sherliker P, et al. Seasonal variation in blood pressure and its relationship with outdoor temperature in 10 diverse regions of China: the China Kadoorie Biobank. J Hypertens, 2012; 30(7): 1383-1391. doi: 10.1097/HJH.0b013e32835465b5

[25] Fregly M J, Kikta D C, Threatte R M, et al. Development of hypertension in rats during chronic exposure to cold. J Appl Physiol ( 1985), 1989; 66(2): 741-749. doi: 10.1152/jappl.1989.66.2.741

[26] Kanayama N, Tsujimura R, She L, et al. Cold-induced stress stimulates the sympathetic nervous system, causing hypertension and proteinuria in rats. J Hypertens, 1997; 15(4): 383-389. doi: 10.1097/00004872-199715040-00009

[27] Pan Z, Zhuang J, Zhu C, et al. Impacts of cold-stress stimulation on mice pregnancy. Am J Hypertens, 2023; 36(6): 348-353. doi: 10.1093/ajh/hpad003

[28] Zhu Z, Zhu S, Zhu J, et al. Endothelial dysfunction in cold-induced hypertensive rats. Am J Hypertens, 2002; 15(2 Pt 1): 176-180.

[29] Chen P G, Sun Z. AAV Delivery of endothelin-1 shRNA attenuates cold-induced hypertension. Hum Gene Ther. 2017; 28(2): 190-199. doi: 10.1089/hum.2016.047

[30] Brackett C M, Blagg B S J. Current status of SUMOylation inhibitors. Curr Med Chem, 2021; 28(20): 3892-3912. doi: 10.2174/0929867327666200810135039

[31] Langston S P, Grossman S, England D, et al. Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer. J Med Chem, 2021; 64(5): 2501-2520. doi: 10.1021/acs.jmedchem.0c01491

[32] Chen Z, Cui Q, Cooper L, et al. Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. Cell Biosci, 2021; 11(1): 45. doi: 10.1186/s13578-021-00564-x

[33] Qiu F, Dong C, Liu Y, et al. Pharmacological inhibition of SUMO-1 with ginkgolic acid alleviates cardiac fibrosis induced by myocardial infarction in mice. Toxicol Appl Pharmacol, 2018; 15(345): 1-9.

[34] Esparis-ogando A, Diaz-rodriguez E, Montero J C, et al. Erk 5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol, 2002; 22(1): 270-285. doi: 10.1128/MCB.22.1.270-285.2002

[35] Buschbeck M, Ullrich A. The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem, 2005; 280(4): 2659-2667. doi: 10.1074/jbc.M412599200

[36] Nigro P, Abe J, Woo C H, et al. PKCzeta decreases eNOS protein stability via inhibitory phosphorylation of ERK5. Blood, 2010; 116(11): 1971-1979. doi: 10.1182/blood-2010-02-269134

[37] Angolano C, Kaczmarek E, Essayagh S, et al. A20/TNFAIP 3 increases ENOS expression in an ERK5/KLF2-dependent manner to support endothelial cell health in the face of inflammation. Front Cardiovasc Med, 2021; 8: 651230. doi: 10.3389/fcvm.2021.651230

[38] Li Q, Chen Y, Zhang X, et al. Scutellarin attenuates vasospasm through the Erk5-KLF2-eNOS pathway after subarachnoid hemorrhage in rat. J Clin Neurosci, 2016; 34(2): 64-70.

[39] Lee G H, Park J S, Jin S W, et al. Betulinic acid induces eNOS expression via the AMPK-dependent KLF 2 signaling pathway. J Agric Food Chem, 2020; 68(49): 14523-14530. doi: 10.1021/acs.jafc.0c06250

[40] Heo K S, Fujiwara K, Abe J. Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction. Circ J, 2011; 75(12): 2722-2730. doi: 10.1253/circj.CJ-11-1124

[41] Suzawa M, Miranda D A, Ramos K A, et al. A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver. Elife, 2015; 44: e09003.